Phase III Clinical Trial Development: A Process of Chutes and Ladders
暂无分享,去创建一个
James H. Doroshow | David M. Dilts | Steven K. Cheng | J. Doroshow | D. Dilts | A. Sandler | S. Cheng | Alan B. Sandler | Joshua S. Crites | J. Crites
[1] David M. Dilts,et al. Steps and time to process clinical trials at the Cancer Therapy Evaluation Program. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Michelle A. Mathiason,et al. Nature and outcome of clinical trials conducted by the Eastern Cooperative Group (ECOG) from 1977 to 2006. , 2010 .
[3] S. Nass,et al. Multi-Center Phase III Clinical Trials and NCI Cooperative Groups: Workshop Summary , 2009 .
[4] D. Dilts,et al. A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] D. Steensma. Processes to activate phase III clinical trials in a cooperative oncology group: the elephant is monstrous. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] F. Gao,et al. Time to activate lung cancer clinical trials and patient enrollment: a representative comparison study between two academic centers across the atlantic. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Iztok Hozo,et al. Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. , 2008, Archives of internal medicine.
[8] Roger E. Bohn,et al. Noise and learning in semiconductor manufacturing , 1995 .
[9] M. Gobbi,et al. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] C. Runowicz,et al. Challenges to National Cancer Institute-Supported Cooperative Group Clinical Trial Participation: An ASCO Survey of Cooperative Group Sites. , 2010, Journal of oncology practice.
[11] R. Gray,et al. Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials , 2011, Clinical trials.
[12] Richard L Schilsky,et al. Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] David M Dilts,et al. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] D. Dilts,et al. Accrual to clinical trials at selected comprehensive cancer centers , 2008 .
[15] Robert Gray,et al. Development of Clinical Trials in a Cooperative Group Setting: The Eastern Cooperative Oncology Group , 2008, Clinical Cancer Research.
[16] R. Schilsky. Personalizing cancer care: American Society of Clinical Oncology presidential address 2009. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] E. Emanuel,et al. The costs of conducting clinical research. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Kingshuk K. Sinha,et al. Applying Process Knowledge for Yield Variation Reduction: A Longitudinal Field Study , 2005, Decis. Sci..
[19] Scott D Ramsey,et al. A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. , 2010, Journal of the National Cancer Institute.
[20] D. Dilts,et al. A Sense of Urgency: Evaluating the Link between Clinical Trial Development Time and the Accrual Performance of Cancer Therapy Evaluation Program (NCI-CTEP) Sponsored Studies , 2010, Clinical Cancer Research.
[21] J. Cox. Seeking serenity with influence. , 2010, Journal of oncology practice.